PrimaryCareNOW: Endocrinology Spotlight
         
Thank you to all who joined us live for PrimaryCareNOW on Friday, August 28, 2020. If you were not able to join us, most sessions have been recorded and are available below.

Upcoming Virtual Conferences
Pri-Med has more virtual education planned. View our upcoming virtual conference schedule.

Upcoming Conferences


Agenda

  CME/CE Accredited Session

Non-CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

8–9am ET

Endocrinology


 


Over ten percent of the U.S. population suffers disproportionate cardiometabolic risk because of their type 2 diabetes (T2DM). In light of recent data, GLP-1 receptor agonists (GLP-1 RAs) have taken on a more prominent role in T2DM management algorithms. This session will discuss how you can distinguish among GLP-1 RAs and use them in your practice to help manage the risks that these patients face beyond glucose control.

M. Susan Burke, MD, FACP 

M. Susan Burke, MD, FACP

Clinical Associate Professor of Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Senior Advisor, Lankenau Medical Associates, Lankenau Medical Center, Wynnewood, PA

 

Samuel Dagogo-Jack, MD 

Samuel Dagogo-Jack, MD

Professor of Medicine and Director, Division of Endocrinology, Diabetes, and Metabolism, University of Tennessee Health Science Center, Memphis, TN; Professor of Medicine, University of Tennessee Health Science Center, Memphis, TN

Supported by Novo Nordisk Inc.

9:10am–10:10am ET

Endocrinology

Introduction to Obesity Medicine 

Craig Primack, MD, FACP, FAAP, FOMA


 

This session will provide primary care clinicians with a foundational understanding of the pathophysiology of obesity. We will review the 4-pillar concept of obesity treatment and provide practical skills for applying nutritional interventions, physical activity recommendations, behavioral therapy approaches, and medication treatments for patients with obesity.

Craig Primack, MD, FACP, FAAP, FOMA 

Craig Primack, MD, FACP, FAAP, FOMA

President, Board of Director Obesity Medicine Association

Developed in partnership with Obesity Medicine Association

10:20–11:05am ET

Industry Theater

Defining Moments: Opportunities for Identifying and Treating Hidradenitis Suppurative in
Adolescence and Beyond 

Stephen K. Tyring


 


  • Recognize the central role of primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus (T2DM)
  • Appraise recent data on antihyperglycemic medications with proven cardiovascular (CV) benefit
  • Consult updated T2DM management algorithms that emphasize CV history when considering antihyperglycemic therapies
  • Apply a shared-decision making model to select antihyperglycemic agents based on an individual patient’s CV risk, comorbidities, and preferences

 

Stephen K. Tyring 

Stephen K. Tyring

Houston Skin Associates; Board-Certified by the American Board of Dermatology and Fellow of the American Academy of Dermatology, Infectious Disease Society of America; Founding Member of Dermatological Association of Texas and Center for Clinical Studies

Sponsored by AbbVie - Humira (HS)

10:20–11:05am ET

Industry Theater

 

This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.

Javed Butler, MD, MPH, MBA 

Javed Butler, MD, MPH, MBA

Chairman and Professor Department of Medicine University of Mississippi Jackson, MS

Novartis Pharmaceuticals Corporation

11:15am–12:15pm ET

Endocrinology

The Heart of the Matter: Primary and Secondary Prevention of Cardiovascular Disease in T2DM 

Rachel Bond, MD, FACC | Charles Vega, MD, FAAFP


 

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences.

Rachel Bond, MD, FACC 

Rachel Bond, MD, FACC

 

Charles Vega, MD, FAAFP 

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine; Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine

Supported by Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

12:25–1:10pm ET

Industry Theater


 

  • Understand the link between type 2 diabetes and cardiovascular disease
  • Highlight the risk of heart failure in patients with type 2 diabetes
  • Review considerations and potential implications for reducing hospitalizations for heart failure
  • Review glycemic and nonglycemic effects of SGLT-2i
  • Understand the effects of Farxiga in patients with type 2 diabetes across a broad spectrum of cardiovascular risk
  • Review guideline recommendations for the use of SGLT-2is
Surendra Sivarajah, MD 

Surendra Sivarajah, MD

Field Physician, Biopharmaceuticals, US Medical | CVMD

Sponsored by AstraZeneca Pharmaceuticals, LP


CME/CE Faculty

Rachel Bond, MD, FACC
Rachel Bond, MD, FACC
M. Susan Burke, MD, FACP 
M. Susan Burke, MD, FACP
Samuel Dagogo-Jack, MD 
Samuel Dagogo-Jack, MD
Craig Primack, MD, FACP, FAAP, FOMA
Craig Primack, MD, FACP, FAAP, FOMA
Charles Vega, MD, FAAFP 
Charles Vega, MD, FAAFP